Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, March 29, 2024 · 699,603,725 Articles · 3+ Million Readers

Elucid - mHealth smart pill bottle to monitor patient adherence will communicate with smart watches as well as phones

How it could look on a smart watch. The patient responds to the reminder, touches dispense and the bottle ejects the pill or capsule.

MANCHESTER, UNITED KINGDOM, October 21, 2019 /EINPresswire.com/ -- Elucid- mHealth smart pill bottle to monitor patient adherence will communicate with smart watches as well as phones

The OECD estimates non adherence to pill regimes cause 200,000 premature deaths a year in EU and costs EUR 125 billion in the US $105 billion. Elucid’s Pill Connect system which has now successfully completed a number of robustness and patient compatibility trials is developing the technology to link the bottle directly to a smart watch as well as through a phone.

Dr James Burnstone CEO of Elucid commented “unfortunately many patients don’t take their pills as prescribed. We want to make it as easy as possible both to provide a reminder to the patient and also to let the doctor or researcher know. Smart watches are becoming increasingly popular and it was a natural step to link the bottle to these devices. “

Adherence is a major problem in both clinical trials and in the community. A 2018 report by the US National Institute of Health1 found that “Nonadherence to medications is a worldwide phenomenon and it has been found that in developed countries, adherence rate, expressed as a percent of prescribed doses taken, averages around 50% for chronic illnesses.”

Patients with chronic diseases are particularly vulnerable to poor health outcomes if they do not adhere to their medications. Mortality rates for patients with diabetes and heart disease who don’t adhere are nearly twice as high as for those who do adhere.

How the Pill Connect system works

• Preparation - A patient has an app loaded onto their mobile phone (iPhone or android) which contains the pill regime – eg twice a day. The patient learns how to use the app – 10 minutes - and given a Pill Connect bottle loaded with pills.
• Patient use -The patient receives a reminder to take a pill via the app at a pre-determined time. The patient responds to the reminder and a pill is dispensed and the data sent to a control centre.
• Side effects – If the patient is unwell or believes that they are suffering from a side effect to the medication they have the option to not take the pill and tell the doctor/ investigator why.
• Non – adherence/not wanting to take pill - If the patient does not respond or has a reason why they can’t take the medication, a text or call can be made automatically or manually to prompt adherence or find out the reason for refusal.
• Comprehensive data - The doctor or administrator has comprehensive data on each patients dispensing pattern.
• Safety - The bottle is locked outside the prescribed times to prevent double dosing – particularly common in the elderly.

Elucid is working with a number of healthcare organisations including CROs and pharma who have expressed particular interest for using the system in clinical trials where non adherence can substantially alter the results and for very expensive drugs so that the doctor can track adherence. Regrettably patients don’t admit their adherence and the doctor or researcher makes a decision based on incorrect information which can be to the patient’s detriment.

The Pill Connect dispenser mechanism and electronics are designed to fit onto a standard pill bottle which is easily filled or refilled by a pharmacist. The capacity of the pill bottle will depend upon the pill size but will have a minimum of thirty pills. The dispensing mechanism can be adjusted to handle pills or capsules of different sizes.

About Elucid mHealth
Elucid mHealth is a health technology company based in Manchester, UK developing smart solutions to improve patient care. Pill Connect, Elucid’s smart dispensing system which aims to improve and monitor patient adherence, is running a series of clinical trials over the course of the next few months.
US Patent grants: 9,984,213 and 10,224,116

1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310871/
2https://www.oecd-ilibrary.org/docserver/8178962c-en.pdf?expires=1568713665&id=id&accname=guest&checksum=0FFBBEF4BCDE61F8E8FAE8B25D24CDB8
ww.elucid-mhealth.com/index.html

Simon Vane Percy
Vane Percy & Roberts
+ +44 1737821890
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release